Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | ETTX | Common Stock | Purchase | $7.46M | +3.73M | $2.00 | 3.73M | May 3, 2021 | See Footnote | F1 | |
holding | ETTX | Common Stock | 18.7M | May 3, 2021 | Direct | F2 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | ETTX | Warrants to Purchase Common Stock | Purchase | $7.46M | +3.73M | $2.00 | 3.73M | May 3, 2021 | Common Stock | 3.73M | $2.00 | See footnote | F1 | |
holding | ETTX | Warrants to Purchase Common Stock | 18.7M | May 3, 2021 | Common Stock | 18.7M | Direct | F2 |
Id | Content |
---|---|
F1 | As reflected in the Amendment No. 4 to Schedule 13D filed by Innoviva, Inc. ("INVA") and Innoviva Strategic Opportunities LLC, a wholly owned subsidiary of INVA ("ISO" and together with INVA, the "Reporting Persons") with the U.S. Securities and Exchange Commission on May 3, 2021 (the "Schedule 13D/A"), in connection the closing that occurred on May 3, 2021 pursuant to a securities purchase agreement, dated as of May 3, 2021 (the "Purchase Agreement" and, such closing, the "Closing"), by and between Entasis Therapeutics Holdings Inc. (the "Issuer") and ISO, ISO acquired 3,731,025 shares of common stock of the Issuer ("Shares") and warrants to purchase an additional 3,731,025 Shares ("Warrants" and together with the Shares, the "Security") for an aggregate price of $2.00 per Security as set forth in this Form 4. |
F2 | INVA acquired an aggregate of 18,672,897 shares of common stock of the issuer and warrants to purchase an aggregate 18,672,897 shares of common stock of the Issuer in transactions on April 22, 2020, June 11, 2020 and September 1, 2020. |